Trial intelligence / Profile preview

DANTE / FLOT8

2024-514945-12-00Phase 3Authorised

Sponsor: Institut für Klinische Krebsforschung
Start: Aug 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 2

Overview

Phase 3, randomised, open-label trial of atezolizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoints: Event-free survival and Pathological complete response or tumor regression grade 1a rate. Planned start Aug 2024; status: authorised.

Drugs

atezolizumab

Conditions

gastric cancer (GC)gastroesophageal junction adenocarcinoma

Beyond the preview

Go deeper on 2024-514945-12-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514945-12-00.